Clinically Relevant Pharmacology of Selective Serotonin Reuptake Inhibitors

[1]  D. Greenblatt,et al.  Desipramine pharmacokinetics when coadministered with paroxetine or sertraline in extensive metabolizers. , 1997, Journal of clinical psychopharmacology.

[2]  S. Preskorn,et al.  Cytochrome P450 enzymes: interpretation of their interactions with selective serotonin reuptake inhibitors. Part II. , 1996, Journal of clinical psychopharmacology.

[3]  A. T. Harvey,et al.  Biochemical and clinical dose‐response curves with sertraline , 1996 .

[4]  D. Greenblatt,et al.  In vitro biotransformation of phenacetin to acetaminophen: Metabolic inhibition by antidepressants , 1996 .

[5]  D. Helmeste,et al.  Paroxetine shifts imipramine metabolism , 1996, Psychiatry Research.

[6]  R. Post,et al.  The emerging role of cytochrome P450 3A in psychopharmacology. , 1995, Journal of clinical psychopharmacology.

[7]  D. Greenblatt,et al.  N-demethylation of amitriptyline in vitro: role of cytochrome P-450 3A (CYP3A) isoforms and effect of metabolic inhibitors. , 1995, The Journal of pharmacology and experimental therapeutics.

[8]  J. Mendels,et al.  Sertraline safety and efficacy in major depression: A double-blind fixed-dose comparison with placebo , 1995, Biological Psychiatry.

[9]  S. Preskorn,et al.  Interactions of serotonin reuptake inhibitors with tricyclic antidepressants. , 1995, Archives of general psychiatry.

[10]  K. Chiba,et al.  Comparison of the interaction potential of a new proton pump inhibitor, E3810, versus omeprazole with diazepam in extensive and poor metabolizers of S‐mephenytoin 4′‐hydroxylation , 1995, Clinical pharmacology and therapeutics.

[11]  B. Rochat,et al.  Analysis of Enantiomers of Citalopram and Its Demethylated Metabolites in Plasma of Depressive Patients Using Chiral Reverse‐Phase Liquid Chromatography , 1995, Therapeutic drug monitoring.

[12]  D. Greenblatt,et al.  Inhibition of alprazolam and desipramine hydroxylation in vitro by paroxetine and fluvoxamine: comparison with other selective serotonin reuptake inhibitor antidepressants. , 1995, Journal of clinical psychopharmacology.

[13]  S. Preskorn,et al.  The SSRIs: advantages, disadvantages and differences , 1995, Journal of psychopharmacology.

[14]  B. Rochat,et al.  Comparative pharmacokinetics of selective serotonin reuptake inhibitors: a look behind the mirror , 1995, International clinical psychopharmacology.

[15]  S. Loft,et al.  Selective serotonin reuptake inhibitors and theophylline metabolism in human liver microsomes: potent inhibition by fluvoxamine. , 1995, British journal of clinical pharmacology.

[16]  J. Goldstein,et al.  Biochemistry and molecular biology of the human CYP2C subfamily. , 1994, Pharmacogenetics.

[17]  D. Greenblatt,et al.  Fluoxetine inhibition of phenytoin metabolism. , 1994, Journal of clinical psychopharmacology.

[18]  P. Neuvonen,et al.  Oral triazolam is potentially hazardous to patients receiving systemic antimycotics ketoconazole or itraconazole , 1994, Clinical pharmacology and therapeutics.

[19]  E. Perucca,et al.  Inhibition of diazepam metabolism by fluvoxamine: A pharmacokinetic study in normal volunteers , 1994, Clinical pharmacology and therapeutics.

[20]  P. Goodnick.  Pharmacokinetic Optimisation of Therapy with Newer Antidepressants , 1994, Clinical pharmacokinetics.

[21]  J. Miners,et al.  Diazepam metabolism by human liver microsomes is mediated by both S-mephenytoin hydroxylase and CYP3A isoforms. , 1994, British journal of clinical pharmacology.

[22]  D. Greenblatt,et al.  Inhibitors of alprazolam metabolism in vitro: effect of serotonin-reuptake-inhibitor antidepressants, ketoconazole and quinidine. , 1994, British journal of clinical pharmacology.

[23]  H. Yamazaki,et al.  Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. , 1994, The Journal of pharmacology and experimental therapeutics.

[24]  D. Kroetz,et al.  Human liver carbamazepine metabolism. Role of CYP3A4 and CYP2C8 in 10,11-epoxide formation. , 1994, Biochemical pharmacology.

[25]  S. Preskorn.  Targeted pharmacotherapy in depression management: comparative pharmacokinetics of fluoxetine, paroxetine and sertraline. , 1994 .

[26]  S. Preskorn,et al.  Pharmacokinetics of desipramine coadministered with sertraline or fluoxetine. , 1994, Journal of clinical psychopharmacology.

[27]  A. Altamura,et al.  Clinical Pharmacokinetics of Fluoxetine , 1994, Clinical pharmacokinetics.

[28]  R. Kato,et al.  Cytochrome P450 mediated metabolism of diazepam in human and rat: involvement of human CYP2C in N-demethylation in the substrate concentration-dependent manner. , 1993, Pharmacogenetics.

[29]  M. Swims,et al.  Potential Terfenadine-Fluoxetine Interaction , 1993, The Annals of pharmacotherapy.

[30]  Gidal Be,et al.  Evaluation of the effect of fluoxetine on the formation of carbamazepine epoxide. , 1993 .

[31]  J. Cummings,et al.  The neuroanatomy of depression. , 1993, The Journal of clinical psychiatry.

[32]  K. Brøsen.  Isozyme specific drug oxidation: Genetic polymorphism and drug-drug interactions , 1993, European Neuropsychopharmacology.

[33]  S. Wrighton,et al.  Interaction of the enantiomers of fluoxetine and norfluoxetine with human liver cytochromes P450. , 1993, The Journal of pharmacology and experimental therapeutics.

[34]  S. Ohmori,et al.  Studies on cytochrome P450 responsible for oxidative metabolism of imipramine in human liver microsomes. , 1993, Biological & pharmaceutical bulletin.

[35]  D. Wong,et al.  Norfluoxetine Enantiomers as Inhibitors of Serotonin Uptake in Rat Brain , 1993, Neuropsychopharmacology.

[36]  A. Avenoso,et al.  Carbamazepine coadministration with fluoxetine or fluvoxamine. , 1993, Therapeutic drug monitoring.

[37]  E. Perucca,et al.  Effect of Fluvoxamine on the Pharmacokinetics of Imipramine and Desipramine in Healthy Subjects , 1993, Therapeutic drug monitoring.

[38]  P. Janicak.  Principles and Practice of Psychopharmacotherapy , 1993 .

[39]  S. Preskorn.  Recent pharmacologic advances in antidepressant therapy for the elderly. , 1993, The American journal of medicine.

[40]  P. Beaune,et al.  Major pathway of imipramine metabolism is catalyzed by cytochromes P-450 1A2 and P-450 3A4 in human liver. , 1993, Molecular pharmacology.

[41]  E. Sellers,et al.  Inhibition by fluoxetine of cytochrome P450 2D6 activity , 1993, Clinical pharmacology and therapeutics.

[42]  S. Loft,et al.  Fluvoxamine is a potent inhibitor of cytochrome P4501A2. , 1993, Biochemical pharmacology.

[43]  H. Möller,et al.  Plasma concentrations of fluvoxamine and maprotiline in major depression: implications on therapeutic efficacy and side effects , 1993, European Neuropsychopharmacology.

[44]  J. Harten.  Clinical Pharmacokinetics of Selective Serotonin Reuptake Inhibitors , 1993 .

[45]  A. Hiller,et al.  A potentially hazardous interaction between erythromycin and midazolam , 1993 .

[46]  K. Brøsen,et al.  Pharmacokinetics of Citalopram in Relation to the Sparteine and the Mephenytoin Oxidation Polymorphisms , 1993, Therapeutic drug monitoring.

[47]  S. Sindrup,et al.  Citalopram: Interaction Studies with Levomepromazine, Imipramine, and Lithium , 1993, Therapeutic drug monitoring.

[48]  J. Miners,et al.  Site-directed mutation studies of human liver cytochrome P-450 isoenzymes in the CYP2C subfamily. , 1993, The Biochemical journal.

[49]  J. Miners,et al.  Co-regulation of phenytoin and tolbutamide metabolism in humans. , 1992, British journal of clinical pharmacology.

[50]  M. Raghoebar,et al.  Single and Multiple Oral Dose Fluvoxamine Kinetics in Young and Elderly Subjects , 1992, Therapeutic drug monitoring.

[51]  D. Greenblatt,et al.  Fluoxetine impairs clearance of alprazolam but not of clonazepam , 1992, Clinical pharmacology and therapeutics.

[52]  K. Wesnes,et al.  Fluvoxamine does not interact with alcohol or potentiate alcohol‐related impairment of cognitive function , 1992, Clinical pharmacology and therapeutics.

[53]  R. Fuller,et al.  Comparison of norfluoxetine enantiomers as serotonin uptake inhibitors in vivo , 1992, Neuropharmacology.

[54]  E. Skjelbo,et al.  Inhibitors of imipramine metabolism by human liver microsomes. , 1992, British journal of clinical pharmacology.

[55]  G. Tucker,et al.  The effect of selective serotonin re-uptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes. , 1992, British journal of clinical pharmacology.

[56]  G. Tucker,et al.  The role of cytochrome P4502D6 in the metabolism of paroxetine by human liver microsomes. , 1992, British journal of clinical pharmacology.

[57]  J. Hallas,et al.  The relationship between paroxetine and the sparteine oxidation polymorphism , 1992, Clinical pharmacology and therapeutics.

[58]  D. Sechter,et al.  Carbamazepine, fluvoxamine. Is there a pharmacokinetic interaction? , 1992, Therapie.

[59]  R. Bergstrom,et al.  Quantification and mechanism of the fluoxetine and tricyclic antidepressant interaction , 1992, Clinical pharmacology and therapeutics.

[60]  K. Brøsen,et al.  Pharmacokinetics of the selective serotonin reuptake inhibitor paroxetine: Nonlinearity and relation to the sparteine oxidation polymorphism , 1992, Clinical pharmacology and therapeutics.

[61]  V. Caillard,et al.  Sertraline in the Prevention of Depression , 1992, British Journal of Psychiatry.

[62]  G. Dunbar,et al.  Optimal dose regimen for paroxetine. , 1992, The Journal of clinical psychiatry.

[63]  Warrington Sj.  Clinical implications of the pharmacology of sertraline. , 1991 .

[64]  J. Fritze,et al.  Interaction between carbamazepine and fluvoxamine , 1991, Acta psychiatrica Scandinavica.

[65]  A. Sperber.  Toxic Interaction Between Fluvoxamine and Sustained Release Theophylline in an 11-Year-Old Boy , 1991, Drug safety.

[66]  M. Dam,et al.  No influence of the antidepressant paroxetine on carbamazepine, valproate and phenytoin , 1991, Epilepsy Research.

[67]  D. Touw,et al.  Fluoxetine and parkinsonism in patients taking carbamazepine. , 1991, The American journal of psychiatry.

[68]  D W Nebert,et al.  Proposed role of drug-metabolizing enzymes: regulation of steady state levels of the ligands that effect growth, homeostasis, differentiation, and neuroendocrine functions. , 1991, Molecular endocrinology.

[69]  T. Andersson.  Omeprazole Drug Interaction Studies , 1991, Clinical pharmacokinetics.

[70]  M. Jann,et al.  Increased carbamazepine plasma concentrations after fluoxetine coadministration , 1991, Clinical pharmacology and therapeutics.

[71]  S. Preskorn,et al.  Antidepressant Response and Plasma Concentrations of Fluoxetine , 1991 .

[72]  J. Miners,et al.  Tolbutamide and phenytoin hydroxylations by cDNA-expressed human liver cytochrome P4502C9. , 1991, Biochemical and biophysical research communications.

[73]  N. S. Harvey,et al.  Compliance, the LAQ, and a new laboratory method of measuring RBC lithium. , 1990, The Journal of clinical psychiatry.

[74]  C. Kaye,et al.  A review of the metabolism and pharmacokinetics of paroxetine in man , 1989, Acta psychiatrica Scandinavica. Supplementum.

[75]  J. Hulse,et al.  Evaluation of the potential for interactions of paroxetine with diazepam, cimetidine, warfarin, and digoxin , 1989, Acta psychiatrica Scandinavica. Supplementum.

[76]  M. Byrne,et al.  The pharmacokinetics of paroxetine in renal impairment , 1989, Acta psychiatrica Scandinavica. Supplementum.

[77]  W. Greb,et al.  The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine , 1989, Acta psychiatrica Scandinavica. Supplementum.

[78]  C. Bye,et al.  Paroxetine plasma levels: lack of correlation with efficacy or adverse events , 1989, Acta psychiatrica Scandinavica. Supplementum.

[79]  L. Bertilsson,et al.  Importance of genetic factors in the regulation of diazepam metabolism: Relationship to S‐mephenytoin, but not debrisoquin, hydroxylation phenotype , 1989, Clinical pharmacology and therapeutics.

[80]  M. Garvey,et al.  Serum Fluoxetine and Norfluoxetine Concentrations and Antidepressant Response , 1989, Therapeutic drug monitoring.

[81]  S. Montgomery,et al.  The Prophylactic Efficacy of Fluoxetine in Unipolar Depression , 1988, British Journal of Psychiatry.

[82]  N. Farid,et al.  Clinical Pharmacology and Pharmacokinetics of Fluoxetine: A Review , 1988, British Journal of Psychiatry.

[83]  S. Schenker,et al.  Fluoxetine disposition and elimination in cirrhosis , 1988, Clinical pharmacology and therapeutics.

[84]  R. Bergstrom,et al.  The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam , 1988, Clinical pharmacology and therapeutics.

[85]  P. Tyrer,et al.  Changes in human whole blood 5-hydroxytryptamine (5-HT) and platelet 5-HT uptake during treatment with paroxetine, a selective 5-HT uptake inhibitor , 1987, Journal of psychopharmacology.

[86]  A. Durand,et al.  Citalopram--a highly selective 5-HT uptake inhibitor--in the treatment of depressed patients. , 1987, International clinical psychopharmacology.

[87]  P. Benfield,et al.  Fluoxetine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depressive illness. , 1986, Drugs.

[88]  P. L. Mikkelsen,et al.  Paroxetine in the treatment of depression ‐ a randomized comparison with amitriptyline , 1985, Acta psychiatrica Scandinavica.

[89]  L Lemberger,et al.  Fluoxetine: clinical pharmacology and physiologic disposition. , 1985, The Journal of clinical psychiatry.

[90]  J. Cohn,et al.  Double-blind comparative trials of fluoxetine and doxepin in geriatric patients with major depressive disorder. , 1985, The Journal of clinical psychiatry.

[91]  G. Aronoff,et al.  Fluoxetine kinetics and protein binding in normal and impaired renal function , 1984, Clinical pharmacology and therapeutics.

[92]  A. Coppen,et al.  Drug plasma levels and platelet 5-HT uptake inhibition during long-term treatment with fluvoxamine or lithium in patients with affective disorders. , 1983, British journal of clinical pharmacology.

[93]  H. Rowe,et al.  The effect of fluoxetine on warfarin metabolism in the rat and man. , 1978, Life sciences.

[94]  S. Preskorn,et al.  Effect of Sertraline on the Pharmacokinetics and Protein Binding of Diazepam in Healthy Volunteers , 1997, Clinical pharmacokinetics.

[95]  L. Tremaine,et al.  Pharmacokinetics of Sertraline and its N-Demethyl Metabolite in Elderly and Young Male and Female Volunteers , 1997, Clinical pharmacokinetics.

[96]  S. Preskorn,et al.  A Study of the Potential Effect of Sertraline on the Pharmacokinetics and Protein Binding of Tolbutamide , 1997, Clinical pharmacokinetics.

[97]  K. Wilner,et al.  Effect of Sertraline on Protein Binding of Warfarin , 1997, Clinical pharmacokinetics.

[98]  S. Williams,et al.  Absence of a sertraline-mediated effect on the pharmacokinetics and pharmacodynamics of carbamazepine. , 1996, The Journal of clinical psychiatry.

[99]  S. Williams,et al.  Absence of effect of sertraline on the pharmacokinetics and pharmacodynamics of phenytoin. , 1996, The Journal of clinical psychiatry.

[100]  S. Preskorn.  Comparison of the tolerability of bupropion, fluoxetine, imipramine, nefazodone, paroxetine, sertraline, and venlafaxine. , 1995, The Journal of clinical psychiatry.

[101]  Paul Benfield,et al.  Fluvoxamine , 1994 .

[102]  J. Hyttel.  Comparative pharmacology of selective serotonin re-uptake inhibitors (SSRIs) , 1993 .

[103]  M. J. Coon,et al.  The P450 superfamily: update on new sequences, gene mapping, accession numbers, early trivial names of enzymes, and nomenclature. , 1993, DNA and cell biology.

[104]  G. Bertschy,et al.  Pharmacodynamic and pharmacokinetic interactions of selective serotonin re-uptake inhibiting antidepressants (SSRIs) with other psychotropic drugs , 1993 .

[105]  Trevor R. Norman,et al.  Relationship between antidepressant response and plasma concentrations of fluoxetine and norfluoxetine , 1993, International clinical psychopharmacology.

[106]  E. Richelson,et al.  Blockade by newly-developed antidepressants of biogenic amine uptake into rat brain synaptosomes. , 1993, Life sciences.

[107]  F. Gonzalez,et al.  Human cytochromes P450: problems and prospects. , 1992, Trends in pharmacological sciences.

[108]  G. Bertschy,et al.  PHARMACOKINETICS OF FLUOXETINE AND FLUVOXAMINE IN DEPRESSED PATIENTS: PERSONAL RESULTS , 1992, Clinical neuropharmacology.

[109]  T. Aoyama,et al.  Hydroxylation of warfarin by human cDNA-expressed cytochrome P-450: a role for P-4502C9 in the etiology of (S)-warfarin-drug interactions. , 1992, Chemical research in toxicology.

[110]  D. Wong,et al.  Fluoxetine and its two enantiomers as selective serotonin uptake inhibitors. , 1990, Acta pharmaceutica Nordica.

[111]  R. Branch,et al.  Genetic polymorphism of S-mephenytoin hydroxylation. , 1989, Pharmacology & therapeutics.

[112]  M. V. Miles,et al.  Erythromycin effects on multiple-dose carbamazepine kinetics. , 1989, Therapeutic drug monitoring.

[113]  J. Wernicke,et al.  Low-dose fluoxetine therapy for depression. , 1988, Psychopharmacology bulletin.

[114]  R. Zerbe,et al.  Fixed-dose fluoxetine therapy for depression. , 1987, Psychopharmacology bulletin.